SlideShare ist ein Scribd-Unternehmen logo
1 von 25
Downloaden Sie, um offline zu lesen
DOTS
DIRECTLY OBSERVED
TREATMENT SHORT
COURSE
REHMANI SAMEERAH IBTISAM
ROLL NUMBER 198
What is DOTS?
DOTS is a comprehensive strategy recommended by
WHO for the detection and cure of tuberculosis.
A trained health care worker or a designated
individual provides the prescribed anti-tuberculous
drugs and watches the patient swallow every dose.1
PROCEDURE:
Patients with infectious tuberculosis are:
 Identified using microscopy services.
 Health workers then observe and record patients
swallowing the full course of the correct dosage of
anti-TB medicines for 6 to 8months.
 Sputum smear testing is repeated after two months,
to check progress, and at the end of treatment.
 A recording and reporting system documents
patients' progress throughout, and the final outcome
of treatment.
HISTORY OF DOTS:
During World War II : Styblo at 24 years of age, contracts
tuberculosis at a concentration camp.
1980: Styblo defines IUATLD model to control TB in
Tanzania2
1990: World Bank asks Styblo to create Pilot project for
China
1993: WHO declares TB as a global emergency
1994: New TB control framework [Dr Arata Kochi]
1995: DOTS launched as a WHO strategy
Dr. Karel Styblo [1921-1998]3
The five components of DOTS4:
1. Effective political and administrative commitment.
2. Case finding primarily by microscopic examination
of sputum of patients presenting to health
facilities.
3. Short-course chemotherapy given under direct
observation.
4. An effective drug supply and management
system.
5. Systematic monitoring and evaluation system.
1. Effective political and
administrative commitment.
Sustained political commitment at all levels with
provision of adequate and competent resources
required for the program including infrastructure as
well as manpower.
Local partnership and commitment.
Provision of adequate funding.
Recognition of TB as a public health responsibility
and priority.
2. Case detection through quality-
assured bacteriology
Bacteriology remains the recommended method of
TB case detection, first using sputum smear
microscopy and then culture and drug susceptibility
testing.
Adequate provision of high quality diagnostic
laboratories, microscopes, lab workers and reporting
facilities.
3. Short-course chemotherapy given
under direct observation.
Provision of standardized treatment according to
WHO which includes a 6 or 8 months
regimen(2HRZE/4HR)5
Provision of treatment under supervision of a health
worker or designated individual.
4. An effective drug supply and
management system
 An uninterrupted and sustained supply of quality
assured anti-TB drugs free of cost is fundamental to
TB control.
 Legislation related to drug regulation should be in
place, and use of anti-TB drugs by all providers
should be strictly monitored
5. Monitoring and evaluation system
Maintaining a standardized recording of individual
patient data, which can be used at the facility level to
monitor treatment outcomes, to identify local problems
as they arise, and to evaluate the performance of each
country.
DOTS IN PAKISTAN:
Pakistan ranks 8th amongst the top 22 TB burden
countries in the world. According to estimates about
300,000 new cases are added each year with Punjab
having a quarter of the total disease burden.6
DOTS program was started in Pakistan in 1995, under
the National TB Control Program however the non-
availability of funds from regular health budget brought it
to a halt.
In 2000, it was revived and funds were allocated to it
seeking to provide 100% TB care to its population by
2005.
By 2005, DOTS had been set up all over Pakistan.
TARGET:
 Increase cure rates to 85% and above.
 Increase case detection to 70%.
 100% DOTS coverage by 2005.
 Reduce mortality and morbidity from TB by 50% by
the year 2010.
 To achieve Millennium Development Goals by
2015.
ACHIEVEMENTS:
 DOTS coverage in Pakistan achieved in May 2005
 Achievement of TB related MDG Targets by 2008
 DOTS expansion to 36 districts of Punjab.
 Capacity building of districts; Training of doctors and
paramedics, at all levels healthcare.
 Expansion of laboratories network.
 Advocacy, communication and social mobilization:
media, news letter, billboards.
 Engaging all care providers: Private as well as
public.
Pakistan - tuberculosis treatment
success rate7:
0
10
20
30
40
50
60
70
80
90
100
1994
1995
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
SUCCESS RATE
SUCCESS RATE
CHALLENGES:
 Financial constraints.
 Emergence of MDR-TB and HIV.
 Capacity building constraints.
 Inadequate laboratory services.
 Inadequate information systems.
 Unaccounted migration from high prevalence areas
with inadequate DOTS coverage.
Why DOTS?
 To ensure adherence to treatment regimen.
 To check for side effects if any.
 To decrease the risk of drug resistance caused by
incomplete treatment.
 To enforce standard protocol for the detection and
treatment of tuberculosis as recommended by
WHO.
 For maintenance of proper recording and
monitoring system.
 Diagnosis is simple, and treatment cures over 95%
of patients in clinical trials.
THE STOP TB PARTNERSHIP
The Stop TB Strategy:
WHO developed a new six point Stop TB Strategy in
2000 which builds on the success of DOTS while also
explicitly addressing the key challenges facing TB.
Vision: A world free of TB.
Goal: To reduce dramatically the global burden of TB
by 2015 in line with the MDGs and the Stop TB
targets,to achieve major progress in the research and
development for tuberculosis cure.
To eliminate tb by 2050.
OBJECTIVES:
To achieve universal access to high
quality diagnosis and treatment for
people with TB.
 To reduce the suffering and socio-
economic burden associated with TB.
To protect poor and vulnerable populations from
TB, TB/HIV and MDR-TB.
 To support the development of new tools
and enable their timely and effective use.
COMPONENTS:
1. Pursue high-quality DOTS expansion and
enhancement.
2. Address TB/HIV, MDR-TB and other challenges.
3. Contribute to health system strengthening.
4. Engage all care providers.
5. Empower people against tuberculosis.
6. Enable and promote research.
Dots
DOTS PLUS:
DOTS- Plus is a new strategy that is designed to manage
MDR-TB in resource limited countries.
Drug-resistant TB is caused by inconsistent, partial or
incorrect treatment of drug-susceptible TB.
MDR-TB is a specific form of drug resistant TB that is
resistant to at least Isoniazid and Rifampicin, the two most
powerful first-line anti-TB drugs.
Treatment regimen includes the use of 2nd line anti-TB
drugs that are expensive and required to be taken for a
longer time with greater side effects.
REFERENCES:
1. http://www.cdc.gov/tb/education/ssmodules/modul
e9/ss9reading2.htm
2. http://www.who.int/tb/publications
3. http://www.scienceheroes.com
4. http://www.who.int/tb/dots
5. Treatment of tuberculosis 4th edition,WHO
6. http://health.punjab.gov.pk/?q=tb_control_program
7. http://www.indexmundi.com/facts/pakistan/tubercu
losis-treatment-success-rate
Dots

Weitere ähnliche Inhalte

Was ist angesagt?

Revised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaRevised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaKavya .
 
Universal immunisation program
Universal immunisation programUniversal immunisation program
Universal immunisation programShivangi dixit
 
National Leprosy Eradication Programme (NLEP)
National Leprosy Eradication Programme (NLEP)National Leprosy Eradication Programme (NLEP)
National Leprosy Eradication Programme (NLEP)Kavya .
 
National malaria control programe
National malaria control programeNational malaria control programe
National malaria control programeMAULIK CHAUDHARI
 
Primary health care slide share
Primary health care  slide sharePrimary health care  slide share
Primary health care slide shareanjalatchi
 
Chronic obstructive pulmonary disorders COPD
Chronic obstructive pulmonary disorders COPDChronic obstructive pulmonary disorders COPD
Chronic obstructive pulmonary disorders COPDANILKUMAR BR
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis pptUma Binoy
 
National AIDS Control Programme NACP
National AIDS Control Programme NACPNational AIDS Control Programme NACP
National AIDS Control Programme NACPHarsh Rastogi
 
Tuberculosis- management and treatment
Tuberculosis- management and treatmentTuberculosis- management and treatment
Tuberculosis- management and treatmentKapil Sharma Neupane
 
National tuberculosis control programme
National tuberculosis control programmeNational tuberculosis control programme
National tuberculosis control programmeSoumya Ranjan Parida
 
Pulse polio immunizaton program
Pulse polio immunizaton programPulse polio immunizaton program
Pulse polio immunizaton programJobin Jacob
 
National immunization programme
National immunization programmeNational immunization programme
National immunization programmeAnju sapkota
 

Was ist angesagt? (20)

ORS
ORSORS
ORS
 
Revised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaRevised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in India
 
Universal immunisation program
Universal immunisation programUniversal immunisation program
Universal immunisation program
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
National Leprosy Eradication Programme (NLEP)
National Leprosy Eradication Programme (NLEP)National Leprosy Eradication Programme (NLEP)
National Leprosy Eradication Programme (NLEP)
 
National malaria control programe
National malaria control programeNational malaria control programe
National malaria control programe
 
Diarrhea disease
Diarrhea diseaseDiarrhea disease
Diarrhea disease
 
National AIDS Control Programme
National AIDS Control ProgrammeNational AIDS Control Programme
National AIDS Control Programme
 
Primary health care slide share
Primary health care  slide sharePrimary health care  slide share
Primary health care slide share
 
Chronic obstructive pulmonary disorders COPD
Chronic obstructive pulmonary disorders COPDChronic obstructive pulmonary disorders COPD
Chronic obstructive pulmonary disorders COPD
 
National health programme
National health programmeNational health programme
National health programme
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis ppt
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
National AIDS Control Programme NACP
National AIDS Control Programme NACPNational AIDS Control Programme NACP
National AIDS Control Programme NACP
 
RNTCP programme.pdf
RNTCP programme.pdfRNTCP programme.pdf
RNTCP programme.pdf
 
Tuberculosis- management and treatment
Tuberculosis- management and treatmentTuberculosis- management and treatment
Tuberculosis- management and treatment
 
National tuberculosis control programme
National tuberculosis control programmeNational tuberculosis control programme
National tuberculosis control programme
 
Pulse polio immunizaton program
Pulse polio immunizaton programPulse polio immunizaton program
Pulse polio immunizaton program
 
National immunization programme
National immunization programmeNational immunization programme
National immunization programme
 
BCG vaccine
BCG vaccineBCG vaccine
BCG vaccine
 

Ähnlich wie Dots

Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programmeRavi Rohilla
 
National tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxNational tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxSanaKhader1
 
Rntcp and national strategic plan(nsp) for tb
Rntcp and national strategic plan(nsp) for tbRntcp and national strategic plan(nsp) for tb
Rntcp and national strategic plan(nsp) for tbWal
 
Global and Indian plan to End TB
Global and Indian plan to End TBGlobal and Indian plan to End TB
Global and Indian plan to End TBRama shankar
 
TB control programs in nepal
TB control programs in nepalTB control programs in nepal
TB control programs in nepalSurakshya Poudel
 
Reasons for innovations and changing strategies in RNTCP 2019
Reasons for innovations and changing strategies in RNTCP 2019Reasons for innovations and changing strategies in RNTCP 2019
Reasons for innovations and changing strategies in RNTCP 2019Drsadhana Meena
 
Tuberculosis National Health Program in Nepal
Tuberculosis National Health Program  in Nepal Tuberculosis National Health Program  in Nepal
Tuberculosis National Health Program in Nepal Public Health
 
critical review_RNTCP1 -
critical review_RNTCP1 -critical review_RNTCP1 -
critical review_RNTCP1 -Isha Porwal
 
cessation of smocking (2).pptx
cessation of smocking (2).pptxcessation of smocking (2).pptx
cessation of smocking (2).pptxAshraf Shaik
 
National Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptxNational Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptxDarshnaSarvaiya2
 
tb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdftb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdfanchalyadav895389
 

Ähnlich wie Dots (20)

END TB 2015 strategy
END TB 2015 strategyEND TB 2015 strategy
END TB 2015 strategy
 
ntep.pptx
ntep.pptxntep.pptx
ntep.pptx
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programme
 
National tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxNational tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptx
 
RNTCP.pptx
RNTCP.pptxRNTCP.pptx
RNTCP.pptx
 
Rntcp and national strategic plan(nsp) for tb
Rntcp and national strategic plan(nsp) for tbRntcp and national strategic plan(nsp) for tb
Rntcp and national strategic plan(nsp) for tb
 
Global and Indian plan to End TB
Global and Indian plan to End TBGlobal and Indian plan to End TB
Global and Indian plan to End TB
 
TB control programs in nepal
TB control programs in nepalTB control programs in nepal
TB control programs in nepal
 
End tb
End tbEnd tb
End tb
 
Tb control in india
Tb control in indiaTb control in india
Tb control in india
 
RNTCP ARPIT.pptx
RNTCP ARPIT.pptxRNTCP ARPIT.pptx
RNTCP ARPIT.pptx
 
Reasons for innovations and changing strategies in RNTCP 2019
Reasons for innovations and changing strategies in RNTCP 2019Reasons for innovations and changing strategies in RNTCP 2019
Reasons for innovations and changing strategies in RNTCP 2019
 
Tuberculosis National Health Program in Nepal
Tuberculosis National Health Program  in Nepal Tuberculosis National Health Program  in Nepal
Tuberculosis National Health Program in Nepal
 
National tb program
National tb programNational tb program
National tb program
 
critical review_RNTCP1 -
critical review_RNTCP1 -critical review_RNTCP1 -
critical review_RNTCP1 -
 
cessation of smocking (2).pptx
cessation of smocking (2).pptxcessation of smocking (2).pptx
cessation of smocking (2).pptx
 
National Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptxNational Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptx
 
tb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdftb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdf
 
Komal hirani
Komal hiraniKomal hirani
Komal hirani
 
333.pptx
333.pptx333.pptx
333.pptx
 

Kürzlich hochgeladen

PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 

Kürzlich hochgeladen (20)

PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 

Dots

  • 1. DOTS DIRECTLY OBSERVED TREATMENT SHORT COURSE REHMANI SAMEERAH IBTISAM ROLL NUMBER 198
  • 2. What is DOTS? DOTS is a comprehensive strategy recommended by WHO for the detection and cure of tuberculosis. A trained health care worker or a designated individual provides the prescribed anti-tuberculous drugs and watches the patient swallow every dose.1
  • 3. PROCEDURE: Patients with infectious tuberculosis are:  Identified using microscopy services.  Health workers then observe and record patients swallowing the full course of the correct dosage of anti-TB medicines for 6 to 8months.  Sputum smear testing is repeated after two months, to check progress, and at the end of treatment.  A recording and reporting system documents patients' progress throughout, and the final outcome of treatment.
  • 4. HISTORY OF DOTS: During World War II : Styblo at 24 years of age, contracts tuberculosis at a concentration camp. 1980: Styblo defines IUATLD model to control TB in Tanzania2 1990: World Bank asks Styblo to create Pilot project for China 1993: WHO declares TB as a global emergency 1994: New TB control framework [Dr Arata Kochi] 1995: DOTS launched as a WHO strategy
  • 5. Dr. Karel Styblo [1921-1998]3
  • 6. The five components of DOTS4: 1. Effective political and administrative commitment. 2. Case finding primarily by microscopic examination of sputum of patients presenting to health facilities. 3. Short-course chemotherapy given under direct observation. 4. An effective drug supply and management system. 5. Systematic monitoring and evaluation system.
  • 7. 1. Effective political and administrative commitment. Sustained political commitment at all levels with provision of adequate and competent resources required for the program including infrastructure as well as manpower. Local partnership and commitment. Provision of adequate funding. Recognition of TB as a public health responsibility and priority.
  • 8. 2. Case detection through quality- assured bacteriology Bacteriology remains the recommended method of TB case detection, first using sputum smear microscopy and then culture and drug susceptibility testing. Adequate provision of high quality diagnostic laboratories, microscopes, lab workers and reporting facilities.
  • 9. 3. Short-course chemotherapy given under direct observation. Provision of standardized treatment according to WHO which includes a 6 or 8 months regimen(2HRZE/4HR)5 Provision of treatment under supervision of a health worker or designated individual.
  • 10. 4. An effective drug supply and management system  An uninterrupted and sustained supply of quality assured anti-TB drugs free of cost is fundamental to TB control.  Legislation related to drug regulation should be in place, and use of anti-TB drugs by all providers should be strictly monitored
  • 11. 5. Monitoring and evaluation system Maintaining a standardized recording of individual patient data, which can be used at the facility level to monitor treatment outcomes, to identify local problems as they arise, and to evaluate the performance of each country.
  • 12. DOTS IN PAKISTAN: Pakistan ranks 8th amongst the top 22 TB burden countries in the world. According to estimates about 300,000 new cases are added each year with Punjab having a quarter of the total disease burden.6 DOTS program was started in Pakistan in 1995, under the National TB Control Program however the non- availability of funds from regular health budget brought it to a halt. In 2000, it was revived and funds were allocated to it seeking to provide 100% TB care to its population by 2005. By 2005, DOTS had been set up all over Pakistan.
  • 13. TARGET:  Increase cure rates to 85% and above.  Increase case detection to 70%.  100% DOTS coverage by 2005.  Reduce mortality and morbidity from TB by 50% by the year 2010.  To achieve Millennium Development Goals by 2015.
  • 14. ACHIEVEMENTS:  DOTS coverage in Pakistan achieved in May 2005  Achievement of TB related MDG Targets by 2008  DOTS expansion to 36 districts of Punjab.  Capacity building of districts; Training of doctors and paramedics, at all levels healthcare.  Expansion of laboratories network.  Advocacy, communication and social mobilization: media, news letter, billboards.  Engaging all care providers: Private as well as public.
  • 15. Pakistan - tuberculosis treatment success rate7: 0 10 20 30 40 50 60 70 80 90 100 1994 1995 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 SUCCESS RATE SUCCESS RATE
  • 16. CHALLENGES:  Financial constraints.  Emergence of MDR-TB and HIV.  Capacity building constraints.  Inadequate laboratory services.  Inadequate information systems.  Unaccounted migration from high prevalence areas with inadequate DOTS coverage.
  • 17. Why DOTS?  To ensure adherence to treatment regimen.  To check for side effects if any.  To decrease the risk of drug resistance caused by incomplete treatment.  To enforce standard protocol for the detection and treatment of tuberculosis as recommended by WHO.  For maintenance of proper recording and monitoring system.  Diagnosis is simple, and treatment cures over 95% of patients in clinical trials.
  • 18. THE STOP TB PARTNERSHIP
  • 19. The Stop TB Strategy: WHO developed a new six point Stop TB Strategy in 2000 which builds on the success of DOTS while also explicitly addressing the key challenges facing TB. Vision: A world free of TB. Goal: To reduce dramatically the global burden of TB by 2015 in line with the MDGs and the Stop TB targets,to achieve major progress in the research and development for tuberculosis cure. To eliminate tb by 2050.
  • 20. OBJECTIVES: To achieve universal access to high quality diagnosis and treatment for people with TB.  To reduce the suffering and socio- economic burden associated with TB. To protect poor and vulnerable populations from TB, TB/HIV and MDR-TB.  To support the development of new tools and enable their timely and effective use.
  • 21. COMPONENTS: 1. Pursue high-quality DOTS expansion and enhancement. 2. Address TB/HIV, MDR-TB and other challenges. 3. Contribute to health system strengthening. 4. Engage all care providers. 5. Empower people against tuberculosis. 6. Enable and promote research.
  • 23. DOTS PLUS: DOTS- Plus is a new strategy that is designed to manage MDR-TB in resource limited countries. Drug-resistant TB is caused by inconsistent, partial or incorrect treatment of drug-susceptible TB. MDR-TB is a specific form of drug resistant TB that is resistant to at least Isoniazid and Rifampicin, the two most powerful first-line anti-TB drugs. Treatment regimen includes the use of 2nd line anti-TB drugs that are expensive and required to be taken for a longer time with greater side effects.
  • 24. REFERENCES: 1. http://www.cdc.gov/tb/education/ssmodules/modul e9/ss9reading2.htm 2. http://www.who.int/tb/publications 3. http://www.scienceheroes.com 4. http://www.who.int/tb/dots 5. Treatment of tuberculosis 4th edition,WHO 6. http://health.punjab.gov.pk/?q=tb_control_program 7. http://www.indexmundi.com/facts/pakistan/tubercu losis-treatment-success-rate

Hinweis der Redaktion

  1. www